Rigetti vs. IBM: Which Quantum Computing Stock Has Better Prospects?
As quantum computing inches closer to practical, real-world applications, investors are turning their attention to the companies leading the charge in this transformative technology. Rigetti Computing RGTI and International Business Machines Corporation IBM are two prominent players in the quantum space, each with distinct approaches and advantages. Rigetti, a nimble startup, focuses on building cutting-edge quantum processors and scalable systems, while IBM leverages its decades-long expertise and vast resources to develop a comprehensive quantum ecosystem that integrates hardware, software, and cloud services.
Both companies are rapidly expanding their quantum capabilities and securing partnerships with governments, research institutions, and enterprises eager to use quantum power. As the quantum computing market shifts from experimental research to commercial use, this faceoff compares Rigetti and IBM on technology, business models, and growth strategies, helping investors identify which stock offers better long-term upside in the emerging quantum era.
Shares of Rigetti have plunged 8.2%, while IBM stock has gained 17.6% in the year-to-date period.
Image Source: Zacks Investment Research
From a valuation standpoint, IBM looks more attractive than RGTI. According to the price/book ratio, IBM's shares currently trade at 8.92, lower than 19.43 for Rigetti.
Image Source: Zacks Investment Research
Rigetti uses a modular quantum architecture that scales by linking smaller chips. Its latest Ankaa-3 system features 84 superconducting qubits with approximately 99.5% two-qubit gate fidelity, enabled by its proprietary ABAA process. Rigetti emphasizes AI-assisted calibration and error reduction to boost performance. It plans to launch a 36-qubit system in mid-2025 and exceed 100 qubits by year-end. Though innovative, its systems remain smaller in scale compared to industry leaders.
IBM deploys a highly integrated quantum stack, led by its 133-qubit Heron processor, which improves error rates and reduces crosstalk over its Eagle predecessor. Its modular architecture supports interconnecting processors like the 1,121-qubit Condor, forming the backbone of Quantum System Two for scalable hybrid computing. With strong cloud integration, global infrastructure, and developer support via Qiskit, IBM remains a leader in practical, scalable quantum technology.
Rigetti adopts a focused, hardware-first business model tailored to quantum computing, centered around its proprietary modular chip architecture and cloud-based Quantum Cloud Services. It monetizes through direct system access, strategic partnerships, and integration with platforms like Amazon Braket and Azure Quantum. Rigetti targets niche enterprise and research segments, offering flexible deployment and AI-assisted system calibration.
In contrast, IBM leverages its vast resources to deliver a full-stack quantum computing model, combining hardware, software (Qiskit), and services under the IBM Quantum Platform. It commercializes through cloud access, consulting, and its 280+ member IBM Quantum Network, which includes Fortune 500 firms and academic institutions. With over $1 billion in cumulative quantum revenue and multi-billion-dollar R&D investments, IBM's business model emphasizes ecosystem dominance, global infrastructure, and long-term enterprise integration.
Rigetti's growth strategy centers on scaling modular quantum systems, advancing hardware via ABAA fabrication and AI calibration, and targeting a 108-qubit system by the end of 2025 with halved error rates. It is expanding manufacturing through a $250M Quanta partnership and boosting cloud integration to widen access. While innovation-driven and agile, the strategy is limited by financial constraints and a smaller customer base.
IBM's growth strategy focuses on quantum-centric supercomputing via a long-term roadmap, interconnecting modular chips like the 1,121-qubit Condor to achieve fault tolerance. It targets quantum advantage by 2026 through efforts like the '100×100 challenge' and Quantum System Two. Leveraging global infrastructure, enterprise partnerships, and strong R&D funding, IBM prioritizes scalability, reliability, and commercial adoption worldwide.
The Zacks Consensus Estimate for RGTI's 2025 sales implies a year-over-year decline of 18.63%. For 2025, loss per share is projected to be 5 cents compared with 36 cents a year ago. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for IBM's 2025 sales and earnings implies year-over-year growth of 5.5% and 6%, respectively. The earnings estimates have been trending upward over the past 60 days.
Image Source: Zacks Investment Research
Both Rigetti and IBM are advancing in the quantum computing space, but they differ significantly in scale, strategy, and market positioning. IBM holds a Zacks Rank #3 (Hold) with a strong Growth Score of 'A', reflecting solid potential driven by its expansive infrastructure, global partnerships, and ambitious quantum roadmap. Rigetti, on the other hand, carries a Zacks Rank #4 (Sell), indicating a challenging short-term prospect. However, its Growth score of 'B' reflects upside potential once the challenges subside.
While Rigetti remains a compelling small-cap innovator with modular architecture and technical focus, IBM's full-stack capabilities and enterprise reach give it an edge for investors seeking more stability and long-term commercial traction in the quantum sector. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Rigetti Computing, Inc. (RGTI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. 'The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer,' said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. 'Importantly, we also saw an extension in the duration of time before pain progressed. Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of Tumor Treating Fields therapy concomitant with gemcitabine and nab-paclitaxel to become a standard of care for unresectable, locally advanced pancreatic cancer.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. 'Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis,' said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. 'The results shared today at ASCO and in the Journal of Clinical Oncology demonstrate that Tumor Treating Fields therapy improved overall survival and pain-free survival in unresectable, locally advanced pancreatic cancer. We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy.' Results from PANOVA-3 In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement [hazard ratio (HR) 0.82; p=0.039 (N=571)]. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. Pancreatic cancer can cause significant pain as the disease progresses and managing pain is a key clinical challenge. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with 68.1% [95% CI: 62.0–73.5] compared to those who received gemcitabine and nab-paclitaxel alone, 60.2% [95% CI: 54.2–65.7], p=0.029. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months [95% CI: 10.3–22.8] compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone [95% CI: 7.4–12.7]; HR 0.74 [95% CI: 0.56–0.97], p=0.027. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death. Quality of life was also measured as a secondary endpoint. Analyses were performed for all patients using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum. Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields therapy concomitant with gemcitabine and nab-paclitaxel compared to the gemcitabine and nab-paclitaxel alone group. Full analysis of the quality of life results in PANOVA-3 will be shared at a future scientific conference. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Data Presentation & Publication Details The PANOVA-3 data, (LBA 3500) Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), will be presented today by Dr. Picozzi in Hall D1 during the 3:00 – 6:00 p.m. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary oral session. The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study, will be available online at Novocure Investor Event Novocure will host an investor event featuring Dr. Picozzi and Novocure leadership after the oral presentation. Event details and a link to a live webcast of the event are available on the investor relations page of For more information or to request in-person attendance, please contact Novocure investor relations at investorinfo@ Regulatory & Ongoing Clinical Study of TTFields for Pancreatic Cancer Novocure plans to file for regulatory approval for use of TTFields therapy in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 in the U.S. in the second half of 2025. The company also plans to file for regulatory approval in EU, Japan and other key markets. Novocure continues to follow patients in its Phase 2 PANOVA-4 trial exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in the first half of 2026. About PANOVA-3 PANOVA-3 is an international, prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About PANOVA-4 PANOVA-4 is an international, multi-center, Phase 2 clinical trial designed to test the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The primary endpoint is disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study is designed to enroll 76 patients and enrollment is complete. About Pancreatic Cancer Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the U.S. i While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing. ii It is estimated that approximately 67,000 patients are diagnosed with pancreatic cancer each year in the U.S. iii Pancreatic cancer has a five-year relative survival rate of just 13%. iv Physicians use different combinations of surgery, radiation and pharmacological therapies to treat pancreatic cancer, depending on the stage of the disease. For patients with locally advanced pancreatic cancer involving encasement of arteries but no extra-pancreatic disease, the standard of care is surgery followed by chemotherapy with or without radiation. Unfortunately, most locally advanced cases are diagnosed when the cancer is no longer operable, generally leaving chemotherapy with or without radiation as the only treatment option. About Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe' or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Business Insider
10 hours ago
- Business Insider
Lockheed Martin (LMT) and IBM Show the Real-World Potential of Quantum Computing
Aerospace company Lockheed Martin (LMT) and tech firm IBM (IBM) recently used a new quantum method called sample-based quantum diagonalization (SQD) to simulate the molecule methylene (CH₂), making it the first time SQD has been used on an open-shell molecule. This is a big step forward because SQD could give quantum computers an advantage over classical computers for solving tough chemistry problems, especially those involving complex electron behavior that traditional methods struggle to handle. Confident Investing Starts Here: In their study, the scientists modeled the singlet and triplet electronic states of CH₂, which is important in things like combustion and atmospheric science. They ran the simulations on IBM's 52-qubit quantum processor by using a hybrid setup that combines quantum and classical computing, and each test used up to 3,000 two-qubit gates. Interestingly, the SQD results were very accurate and closely matched what was expected from classical benchmarks known as Selected Configuration Interaction (SCI), especially in measuring bond energies and energy gaps between states. It is worth noting that open-shell molecules like CH₂ are hard to study with classical computers because their unpaired electrons lead to complex interactions that require a lot of computing power. The SQD method helps by avoiding the need to fully rebuild the molecule's wavefunction. Instead, it samples key values and uses quantum properties like electron entanglement to simplify the work. This successful test shows that quantum computing can be used for real chemical problems and could lead to better models for combustion reactions, chemical sensors, and new aerospace materials. What Is the Target Price for IBM? Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on eight Buys, five Holds, and two Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $260.62 per share implies 0.9% upside potential.
Yahoo
13 hours ago
- Yahoo
Making Sense of Q2 Earnings Expectations
We count the Costco COST and AutoZone AZO releases for their respective fiscal quarters ending in May as part of our June-quarter tally. As such, the AutoZone and Costco quarterly reports have kicked off the Q2 earnings season for us, even though we still have a few Q1 earnings releases to await. In fact, by the time the big banks put the spotlight on the Q2 reporting cycle by releasing their June-quarter results on July 14th, we will have seen such May-quarter results from more than two dozen S&P 500 members. Costco handily beat consensus estimates for earnings, revenues, and same-store sales (comps). Same-store sales for the quarter were up +8%, excluding gasoline and the impact of foreign exchange fluctuations. This follows +9.1% comp growth in the preceding period relative to estimates of +6.3%. Of particular significance is the high single-digit comp growth in Costco's non-food merchandise, which can be compared to the discretionary or general merchandise categories at other retailers, such as Walmart and Target. A significant part of Costco's discretionary strength likely reflects the retailer's high-income customer base, but it is also likely gaining market share in these product categories. Costco continues to execute well despite the tariff challenges. Management reiterated on the call that merchandise at the domestic business is mostly sourced from within the U.S., with only about a quarter of Costco U.S. sales dependent on imports. Looking beyond Costco and AutoZone, the expectation is for Q2 earnings for the S&P 500 index to increase by +5.4% from the same period last year on +3.7% higher revenues. This will be a material deceleration from the +12% earnings growth in Q1 on +4.7% revenue growth. We have been regularly flagging in recent weeks that 2025 Q2 earnings estimates have been steadily decreasing, as shown in the chart below. Image Source: Zacks Investment Research The magnitude of cuts to 2025 Q2 estimates since the start of the period is bigger and more widespread relative to what we have become used to seeing in the post-COVID period. Since the start of April, Q2 estimates have declined for 15 of the 16 Zacks sectors (Aerospace is the only sector whose estimates have increased), with the largest cuts to the Transportation, Autos, Energy, Basic Materials, and Construction sectors. Estimates for the Tech and Finance sectors, the largest contributors to the S&P 500 index, which account for more than 50% of all index earnings, have also been cut since the quarter began. But as we have been pointing out in recent weeks, the revisions trend for the Tech sector has notably stabilized, which you can see in the chart below. Image Source: Zacks Investment Research We see this same trend at play in annual estimates as well. The chart below shows the Tech sector's evolving earnings expectations for full-year 2025 Image Source: Zacks Investment Research A likely explanation for this stabilization in the revisions trend is the easing in the tariff uncertainty after the more punitive version of the tariff regime was delayed. Analysts started revising their estimates lower in the immediate aftermath of the early April tariff announcements, but appear to have since concluded that those punitive tariff levels are unlikely to get levied, helping stabilize the revisions trend. The chart below shows current Q2 earnings and revenue growth expectations in the context of the preceding 5 quarters and the coming two quarters. Image Source: Zacks Investment Research The chart below shows the overall earnings picture on a calendar-year basis. Image Source: Zacks Investment Research The Q1 Earnings Scorecard As we noted earlier, the Q1 earnings season isn't over yet. Through Friday, May 30th, we have seen Q1 results from 490 S&P 500 members or 98% of the index's total membership. Total earnings for these 490 index members that have reported results are up +11.9% from the same period last year on +4.8% revenue gains, with 74.1% of the companies beating EPS estimates and 63.3% beating revenue estimates. The comparison charts below put the Q1 earnings and revenue growth rates for these index members in a historical context. Image Source: Zacks Investment Research The comparison charts below put the Q1 EPS and revenue beats percentages in a historical context. Image Source: Zacks Investment Research As you can see here, the EPS and revenue beats percentages are tracking below historical averages, with the Q1 EPS beats percentage of 74.1% comparing to the average for the same group of 78.4% over the preceding 20-quarter period (5 years). The Q1 revenue beats percentage of 63.3% compares to the 5-year average for this group of index members of 71.2%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Costco Wholesale Corporation (COST) : Free Stock Analysis Report AutoZone, Inc. (AZO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
